OTCMKTS:MDFZF Medifocus (MDFZF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medifocus Stock (OTCMKTS:MDFZF) 30 days 90 days 365 days Advanced Chart Get Medifocus alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume74,462 shsMarket Capitalization$18 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medifocus, Inc. is a clinical-stage medical device and biotechnology company focused on developing minimally invasive therapies for common conditions affecting the cardiovascular and urological systems. Headquartered in Carlsbad, California, the company is advancing proprietary MicroSeal™ technology designed to treat small‐to‐medium abdominal aortic aneurysms (AAA) and benign prostatic hyperplasia (BPH). Medifocus’s platform approach utilizes a percutaneous catheter delivery system to deploy a biocompatible sealant, aiming to reduce procedural risks and improve patient outcomes compared with traditional open surgery or permanent implants. The company’s lead product candidate, MicroSeal AAA, is in the investigational stage for use in patients with small aneurysms who are not candidates for conventional endovascular stent grafts. In parallel, Medifocus is developing a MicroSeal application for BPH, targeting men with moderately enlarged prostates who seek an alternative to medication or invasive surgical procedures. Medifocus conducts clinical trials under U.S. Food and Drug Administration (FDA) guidelines and pursues regulatory clearances internationally, with a focus on building strategic partnerships to accelerate market entry and expand its global footprint. Founded in 2004, Medifocus has leveraged over a decade of research and development to refine its proprietary sealant formulation and delivery catheters. With operations in North America and collaborating sites across Europe, the company maintains relationships with leading contract research organizations and manufacturing partners. Medifocus is led by an executive team with extensive experience in medical device innovation, clinical development, and commercialization, supported by a board of directors comprising seasoned life-science entrepreneurs and clinicians. The company continues to advance its pipeline through clinical milestones and aims to bring safer, cost-effective alternatives to patients worldwide.AI Generated. May Contain Errors. Read More Receive MDFZF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifocus and its competitors with MarketBeat's FREE daily newsletter. Email Address MDFZF Stock News HeadlinesMedifocus Successfully Completes Restructuring TransactionAugust 17, 2022 | finance.yahoo.comMedifocus, Inc. Announces SEC Deregistration | MorningstarMay 14, 2022 | morningstar.comMA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. | Porter & Company (Ad)Medifocus, Inc. Announces SEC DeregistrationMay 12, 2022 | finance.yahoo.comMedifocus, Inc.: Medifocus Inc. Announces Plans to Undergo Balance Sheet RestructuringSeptember 19, 2021 | finanznachrichten.deMedifocus Inc. Announces Plans to Undergo Balance Sheet RestructuringSeptember 17, 2021 | finance.yahoo.comSee More Headlines MDFZF Stock Analysis - Frequently Asked Questions How do I buy shares of Medifocus? Shares of MDFZF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/14/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolOTCMKTS:MDFZF CIK1603961 Webwww.medifocusinc.com Phone(410) 290-5734FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares184,980,000Free FloatN/AMarket Cap$18 thousand OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:MDFZF) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifocus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifocus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.